BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIABy Nasdaq OMXMay 9, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual MeetingBy Nasdaq OMXMay 8, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology ConferenceBy Nasdaq OMXMay 2, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual MeetingBy Nasdaq OMXApr 25, 2017, 12:05 PM UTC
BusinessAbeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of SciencesBy Nasdaq OMXApr 5, 2017, 11:43 AM UTC
BusinessAbeona Therapeutics Reports Q4 2016 Financial Results and Business HighlightsBy Nasdaq OMXMar 31, 2017, 12:05 PM UTC
